Lundbeck Eyes US, China Investment as Drug Rewards Lag in Europe
A sign outside the headquarters of H. Lundbeck A/S in Valby, Denmark.
Photographer: Carsten Snejbjerg/BloombergH. Lundbeck A/S will focus its capital investments on the US and China rather than Europe as the region faces growing pressure to incentivize innovation, according to the Danish drugmaker’s chief executive officer.
“We see really strong recognition of innovation in the US. That’s why it’s so attractive,” Charl van Zyl said in an interview, adding China is also advancing in technology and AI-driven discovery. “What we don’t see is the same in Europe.”